Axonics reports first quarter 2024 financial results

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended march 31, 2024. “our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontinence products,” said raymond w. cohen, chief executive.
AXNX Ratings Summary
AXNX Quant Ranking